Patents by Inventor Niels Chresten Berg Nyborg

Niels Chresten Berg Nyborg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
    Patent number: 6960610
    Abstract: The present invention provides methods which may effectively be used in the treatment and prevention of early cardiac and early cardiovascular diseases, for example of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: November 1, 2005
    Assignee: Novo Nordick, A/S
    Inventors: Klaus Asger Rytved, Nils Dragsted, Niels Chresten Berg Nyborg, Lars Iversen, Marit Kristiansen
  • Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
    Publication number: 20040082641
    Abstract: The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.
    Type: Application
    Filed: May 5, 2003
    Publication date: April 29, 2004
    Inventors: Klaus Asger Rytved, Nils Dragsted, Niels Chresten Berg Nyborg, Lars Iversen, Marit Kristiansen
  • Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
    Publication number: 20040082646
    Abstract: The present invention provides methods which may effectively be used in the treatment and prevention of early cardiac and early cardiovascular diseases, for example of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.
    Type: Application
    Filed: May 5, 2003
    Publication date: April 29, 2004
    Inventors: Klaus Asger Rytved, Nils Dragsted, Niels Chresten Berg Nyborg, Lars Iversen, Marit Kristiansen